Chemomab Therapeutics Ltd. (CMMB) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, CMMB scores 31 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 5 / 20 (ROIC -35%; FCF yield 0%). This is the weakest pillar on a cash-generation basis: the business reports a negative return on invested capital and no free-cash-flow yield, so the rating reflects an absence of earnings power rather than a relative discount.
• Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). The lowest pillar score in the set; the source data provides the score but no underlying holder detail (see the Analyst View section).
• Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider signal is scored weak.
• Macro Regime Fit: 8 / 20 (beta 1.0; sector sensitivity). A beta of 1.0 indicates market-equivalent volatility; the score reflects limited fit with the macro regime as assessed by the rating.
• Forensic Balance Sheet: 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The highest pillar, but still only half-credit, with a weak Piotroski reading of 2 out of 9.

For a prospective investor evaluating the stock today, the rating points to a stock where cash generation, insider signal, and institutional flow all score poorly. The upside case would require a change in operating cash economics that the source data does not show; the valuation tradeoff is that a $1.09 share price against an $8.8M market capitalization carries no earnings or cash-flow yield to anchor it. The forensic balance-sheet score is the only pillar with partial support, and it still implies material risk. This is an analytical reading of the rating, not personalized financial advice.

Per the SEC financials, the company reported no revenue in any listed period, with operating income negative in FY 2025 and FY 2024. Margins are 0% on gross, operating, and net bases per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Reported cash fell from $7.6M (FY 2025) to $6.1M (FY 2024), a direction that should be read alongside the negative free cash flow in each reported year.

Per the recent news feed, the principal catalyst is a shareholder vote on a proposed merger set for Dec. 4. Related items reference a financing amount of $10M toward a proposed Scipher merger; the headline's figure is cited as "$10M" in the feed. Other feed items are seasonal-return charts for unrelated tickers (BOLT, HCWB) tagged to CMMB, and a SEC filing dated Nov 2, 2026. All feed items carry a YELLOW light and MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, there are no proprietary signals and no supply-chain links.

Risk watch items: the outcome of the merger vote and whether the financing described is completed; the unexplained inclusion of other-company charts in the CMMB feed, which may affect how news attribution should be read.

• What are the terms, share exchange ratio, and financing structure of the proposed merger, and what happens to CMMB shareholders if the vote on Dec. 4 is approved or rejected?
• What drives the reported operating losses (-$112.0M in FY 2025) given $0.0M revenue, and how is the company funding them against $7.6M of reported cash?
• Which institutional holders, insiders, or Congressional members hold or trade CMMB, given that the holders and analyst sections are empty?
• What are the company's clinical or product pipeline assets, and which of them is the basis for the Biotechnology classification?
• Why do several news items tagged to CMMB reference other tickers (BOLT, HCWB), and is the attribution in the feed reliable?